PFM Health Sciences’s Acadia Pharmaceuticals ACAD Stock Holding History

PFM Health Sciences’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-384,995	Closed	-$5.42M	–	86
2022 Q2	$5.42M	Buy	+384,995	New	+$7.18M	0.21%	73
2021 Q3	–	Sell	-2,807,310	Closed	-$68.5M	–	87
2021 Q2	$68.5M	Buy	2,807,310 +1,505,181	+116%	+$34M	2.15%	16
2021 Q1	$33.6M	Buy	1,302,129 +42,655	+3%	+$1.88M	1.03%	36
2020 Q4	$67.3M	Buy	1,259,474 +838,387	+199%	+$41.6M	2.37%	7
2020 Q3	$17.4M	Buy	+421,087	New	+$18.2M	0.8%	47
2015 Q2	–	Sell	-249,855	Closed	-$8.14M	–	89
2015 Q1	$8.14M	Sell	249,855 -43,710	-15%	-$1.5M	0.22%	74
2014 Q4	$9.32M	Sell	293,565 -267,221	-48%	-$7.58M	0.22%	76
2014 Q3	$13.9M	Sell	560,786 -1,071,389	-66%	-$25.1M	0.32%	47
2014 Q2	$36.9M	Buy	1,632,175 +68,740	+4%	+$1.44M	0.74%	39
2014 Q1	$38M	Buy	+1,563,435	New	+$39.6M	0.69%	41

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PFM Health Sciences's ACAD Position: Q3 2022 in Review

PFM Health Sciences sold out of Acadia Pharmaceuticals (ACAD) in Q3 2022, closing a stake of 384,995 shares — an estimated $5.42M sold.

PFM Health Sciences first reported a position in ACAD in Q1 2014 and held it in 10 quarters. The position peaked at $68.5M in Q2 2021. 222 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

PFM Health Sciences reported no remaining Acadia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
PFM Health Sciences sold 384,995 Acadia Pharmaceuticals shares in Q3 2022, an estimated $5.42M.
PFM Health Sciences first reported a position in Acadia Pharmaceuticals in Q1 2014 and held it in 10 quarters.
PFM Health Sciences's Acadia Pharmaceuticals position peaked at $68.5M in Q2 2021.
222 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on PFM Health Sciences's 13F filing for Q3 2022, filed 14 Nov 2022.